MedTrace Logo

Anti-inflammatories and Adolescent Schizophrenia

NCT04020588 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-09-03

No results posted yet for this study

Summary

A double-blind controlled trial assessing the efficacy of anti-inflammatories on symptoms and cognition of adolescents with schizophrenia

Conditions

Interventions

DRUG

Celecoxib 200mg

Will be administered for 6 weeks

DRUG

Placebo oral capsule

Will be administered for 6 weeks

DRUG

Minocycline 100mg

Will be administered for 6 weeks

Sponsors & Collaborators

  • Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-25
Primary Completion
2020-06-30
Completion
2020-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04020588 on ClinicalTrials.gov